These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 6498336

  • 1. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
    Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyllopoulos DC, Kosow DP.
    Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
    [Abstract] [Full Text] [Related]

  • 2. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM.
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [Abstract] [Full Text] [Related]

  • 3. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
    Smith KJ.
    Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preparation and properties of a therapeutic factor IX concentrate.
    Suomela H, Myllylä G, Raaska E.
    Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
    [Abstract] [Full Text] [Related]

  • 7. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N, Takahashi K, Itoh M, Matsuoka M.
    Bibl Haematol; 1977 Jul; 44():88-93. PubMed ID: 617788
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
    White GC, Roberts HR, Kingdon HS, Lundblad RL.
    Blood; 1977 Feb; 49(2):159-70. PubMed ID: 12845
    [Abstract] [Full Text] [Related]

  • 12. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD.
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [Abstract] [Full Text] [Related]

  • 13. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P.
    Blood; 1992 Feb 01; 79(3):568-75. PubMed ID: 1531035
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
    Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL.
    Am J Hematol; 1992 Jul 01; 40(3):210-5. PubMed ID: 1609775
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Some properties of autoprothrombin II-A anticoagulant.
    Emekli NB, Ulutin ON.
    Bibl Haematol; 1977 Jul 01; 44():15-20. PubMed ID: 617778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.